Eton Pharmaceuticals price target raised to $15 from $11 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $15 from $11 and keeps a Buy rating on the shares after the company announced the acquisition of the U.S. rights to Amglidia.